GSK plc
NYSE:GSK

  • LAST PRICE
    41.9400
  • TODAY'S CHANGE (%)
    0.0900 (0.2151%)
  • Bid / Lots
    41.9300/ 8
  • Ask / Lots
    41.9400/ 7
  • Open / Previous Close
    42.0100 / 41.8500
  • Day Range
    41.9205
    42.0750
  • 52 Week Range
    33.6750
    45.9250
  • Volume
    274,767

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Aug 20, 2024

  • Aug 16, 2024

      Show headlines and story abstract

    • 6:19AM ET on Friday Aug 16, 2024 by Dow Jones
      Companies Mentioned: GSK

      1017 GMT - GSK winning a Florida state court case over a claim that its discontinued heartburn drug Zantac caused prostate cancer is a positive step toward resolving some of the ongoing litigation, JPMorgan analysts say in a note. "Although we take no view on the outcome of litigation, we would view this ruling as an incremental positive for GSK as the ongoing litigation remains a significant overhang on the shares," the analysts say. However, a greater focus lies on updates on the Delaware State Court's Daubert ruling that enabled around 72,000 cases going forward, which GSK has appealed, they say. Daubert standard refers to rules governing the admissibility of expert testimony in Delaware and federal courts. JPMorgan estimates between $1.6 billion and $2.9 billion of settlement costs for its Zantac litigation. Shares fall 0.3%. (helena.smolak@wsj.com)

    • 5:30AM ET on Friday Aug 16, 2024 by Dow Jones
      Companies Mentioned: GSK

      0930 GMT - GSK's Florida state court win is a positive twist in its Zantac litigation saga but concerns continue to cloud the business, AJ Bell Investment director Russ Mould says in a market comment. "The Zantac cloud is overshadowing the progress CEO Emma Walmsley has made in turning around the business and, notwithstanding the good news from Florida, this might continue to prove the case for some time to come," he says. The British pharma giant's continuing legal battle over links between Zantac and cancer remains an issue for the business due to its high case volume, the analyst says. GSK's hope that a similar case dismissal in late 2022 would mark the beginning of the end hasn't materialized yet, he says. The Florida ruling contrasts a Delaware court decision earlier this year that weighs more significantly on GSK, given it accounts for the majority of outstanding cases, Mould says. (helena.smolak@wsj.com)

    • 3:23AM ET on Friday Aug 16, 2024 by Dow Jones
      Companies Mentioned: GSK

      By Helena Smolak

      GSK won a Florida state court lawsuit against a claim that its discontinued heartburn drug Zantac caused prostate cancer, its latest victory in a raft of legal disputes about the treatment.

  • Aug 15, 2024

      Show headlines and story abstract

    • 3:00AM ET on Thursday Aug 15, 2024 by Dow Jones
      Companies Mentioned: GSK
      0700 GMT - GSK's vaccine portfolio will be in focus throughout the year after it posted softer 2Q sales of its best-selling shingles vaccine and ramped up sales of its respiratory syncytial virus vaccine Arexvy, Berenberg analyst Kerry Holford says in a note. The British pharma giant's U.S. Shingrix sales decline should ease into 2H as GSK tackles reimbursement incentives and an inventory restock, he says. In addition, Shingrix sales outside the U.S. will fuel growth where penetration remains below 5% in many regions, the analyst says. GSK remains confident to reach its Arexvy peak sales target this year and Moderna's new RSV vaccine shouldn't be a competitive threat as it missed much of the pharmacy contracting for the next winter season, Berenberg says. "We remain confident in the mid- to long term outlook for both key vaccines," Holford says. (helena.smolak@wsj.com) (END) Dow Jones Newswires August 15, 2024 03:00 ET (07:00 GMT)

Peers Headlines